

38.2. Bone: Spine

Authors

Peter S. Rose, Ginger E. Holt, Andrew E. Rosenberg, Jeffrey S. Kneisl

Emerging Prognostic Factors for Clinical Care

Molecular Abnormalities

Current investigations are searching for molecular abnormalities that provide information related to prognosis and treatment; however, the field is still in the early stage of development. The following summarizes the critical molecular abnormalities of the most important sarcomas of bone.

Critical Molecular Abnormalities of Primary Sarcomas of Bone

Osteosarcoma

High-grade conventional osteosarcoma. Osteosarcomas are characterized by complex DNA copy number alterations, with few recurrent abnormalities and a high level of genomic instability. To date, the search for common molecular therapeutic targets in osteosarcoma has been disappointing. However, the genomic chaos characteristic of osteosarcoma is shedding light on new mutation patterns through recent whole-genome sequencing studies. Approximately 33% of primary osteosarcomas show evidence of *chromothripsis*, defined as a single catastrophic event resulting in massive genomic rearrangements and remodeling of a chromosome, compared with 2–3% of cancers overall. Furthermore, half of all osteosarcomas exhibit *kataegis*, a pattern of localized hypermutation colocalized with regions of somatic genome rearrangements. The regions affected by *kataegis* are not recurrent, and most mutated genes are not located in these regions. Up to 80% of primary osteosarcoma samples harbor RB1 gene aberrations, whereas 20% of osteosarcomas have either a deletion of CDKN2A (encoding p16-INK4A) or an amplification of CDK4. These findings, along with the reciprocal relationship between RB1 and CDKN2A alterations, suggest that G1/S deregulation by RB1 loss, CDK4 amplification, or CDKN2A loss is nearly universal in osteosarcoma. Another gene significantly associated with osteosarcoma is TP53. The frequency of somatic TP53 mutations in osteosarcomas ranges from 19–38%, and TP53 mutations are associated with high levels of genomic instability. An additional 5% of conventional osteosarcomas harbor gene amplification of MDM2. A high copy number gain of the MYC oncogene at 8q24 was found in 43% of osteosarcomas.

Low-grade osteosarcoma. The presence of ring chromosomes resulting from 12q13-15 gains/amplifications is the cytogenetic hallmark of parosteal osteosarcoma. This abnormality may be investigated in clinical practice either by fluorescence *in situ* hybridization (FISH) for MDM2/CDK4 gene

38.2. Bone: Spine

amplifications or by IHC showing overexpression for MDM2 and/or CDK4 in most cases. Thus, MDM2/CDK4 gene amplification and/or protein overexpression represents a useful adjunct test in challenging diagnoses, reliably distinguishing low-grade osteosarcoma from benign histologic mimics. Although a small subset of conventional high-grade osteosarcomas have been documented to harbor MDM2 gene amplifications, it is likely that high-grade osteosarcomas showing coexpression of MDM2 and CDK4 represent dedifferentiated examples of low-grade osteosarcomas; careful examination in these cases to identify the low-grade component, corroborated with detailed radiographic review, might facilitate accurate subclassification.

Although *GNAS* mutations initially were detected exclusively in fibrous dysplasia, a more recent study showed *GNAS* mutations in five of nine cases (55%) of parosteal osteosarcoma, regardless of the presence of a dedifferentiation. These results have not been confirmed in more recent, larger studies, and their validity remains questionable.

Chondrosarcoma

The most prevalent genetic alteration detected in cartilaginous tumors is the somatic mutation of isocitrate dehydrogenase (IDH) genes. Mutations in *IDH1* and *IDH2* are present in 56–61% of chondrosarcomas. Among cartilaginous tumors, IDH mutations appear to be limited to enchondromas, periosteal chondrosarcomas, and central (intramedullary) chondrosarcomas of conventional or dedifferentiated histology. IDH mutations have not been found in secondary peripheral chondrosarcomas, which instead share some of the molecular characteristics of osteochondromas. *IDH1* and *IDH2* mutations also appear to be absent in osteochondromas and osteosarcomas, including chondroblastic osteosarcomas; thus, this molecular test has been proposed as useful in challenging diagnoses. However, a recent report identified the presence of IDH mutations in a subset of conventional osteosarcomas (25%); further studies are needed to validate this finding.

The common IDH mutations in chondrosarcoma affect *IDH1* R132 (~90% of IDH-mutant cases) and *IDH2* at the homologous position, R172 (~10%). These mutations also are common in glioma and acute myeloid leukemia. The mutations block the ability of the enzymes to convert isocitrate to α -ketoglutarate, which in turn increases levels of HIF1A, a subunit of a transcription factor that facilitates tumor growth in hypoxic environments and also interferes with enzymes responsible for demethylation of histones and DNA.

Additionally, a recent whole-exome sequencing study showed that 37% of chondrosarcomas have insertions, deletions, or rearrangements of *COL2A1*, which encodes the α -chain of type II collagen fibers, the major collagen constituent of articular cartilage. These mutations may interfere with the production

38.2. Bone: Spine

of mature collagen fibrils. This study also showed mutations in *IDH1/2* (59%), *TP53* (20%), and genes of the RB1 pathway (33%) and the Hedgehog pathway (18%).

Ewing Sarcoma/PNET

Ewing sarcoma/PNET is characterized by translocations that fuse *EWSR1*, located at chromosome 22q12, and a gene of the ETS family of transcription factors. In 90–95% of cases, there is a recurrent t(11;22)(q24;q12), resulting in an *EWSR1–FLI1* gene fusion, which contains the N-terminal portion of *EWSR1* and the C-terminal portion of *FLI1*. In the *EWSR1–FLI1* fusion protein, the *EWSR1* portion functions as a strong transcriptional activation domain, whereas the *FLI1* portion contributes an ETS-type DNA-binding domain. An *EWSR1–ERG* fusion, resulting from a t(21;22)(q22;q12), is found in 5–10% of cases. Less frequently, *EWSR1* is fused to *ETV1* (7p22), *E1A-F* (17q21), or *FEV* (2q35–36).

EWSR1–FLI1 is structurally heterogeneous, with at least 18 possible types of in-frame *EWSR1–FLI1* chimeric transcripts. The two main types, fusion of *EWSR1* exon 7 to *FLI1* exon 6 (type 1) and fusion of *EWSR1* exon 7 to *FLI1* exon 5 (type 2), account for about 85–90% of *EWSR1–FLI1* fusions. The molecular methods used in clinical practice for detecting this recurrent translocation include reverse transcription polymerase chain reaction (RT-PCR) and FISH. Because of the multiple variants of *EWSR1–FLI1* fusion transcripts, several RT-PCR assays with different primer pair designs typically are needed to reliably exclude the presence of an *EWSR1–FLI1* fusion. Furthermore, depending on fixation methods, the RNA quality extracted from archival material is suboptimal in up to 30–50% of cases. For these technical reasons, FISH testing for the presence of *EWSR1* gene rearrangements has been applied widely and has increasingly replaced the RT-PCR method in most cases. One important caveat regarding FISH assay is that it interrogates abnormalities in only one fusion gene (i.e., *EWSR1*) and does not provide information on the status of its fusion partner; thus, a positive result may be insufficient to rule out other *EWSR1*-rearranged positive mesenchymal neoplasms.

Un/Poorly Differentiated Small Round/Spindle Cell Sarcoma with Alternative Gene Fusions (SRC/SCT)

***EWSR1*-positive small blue round/spindle cell tumors (SRC/SCTs) with alternative non-ETS partners.**

Rare cases of small blue round cell tumors (SRC/SCTs) recently were reported to carry a fusion between *EWSR1* and genes outside the ETS gene family members. Among this group, a few cases showed *EWSR1* fusions with genes encoding a member of the zinc-finger family of proteins, including *EWSR1–PATZ1* or *EWSR1–SP3*; the *NFATc2* gene, encoding for a member of the nuclear factor of activated T cells (NFAT) transcription factor family; or *SMARCA5*, a chromatin-reorganizing gene.

38.2. Bone: Spine

FUS-rearranged SRC/SCTs. In a handful of cases, FUS (fused in sarcoma) has been found to substitute for the *EWSR1* gene, being fused to members of the ETS transcription factor family, with FUS–ERG fusion in five cases and FUS–FEV in one case.

CIC–DUX4–positive SRC/SCTs. CIC–DUX4 fusions are emerging as the most prevalent genetic event in *EWSR1*-negative SRC/SCTs, accounting for two thirds of cases in this group. CIC–DUX4 fusion results from two possible translocation events, either a t(4;19)(q35;q13) or t(10;19)(q26.3;q13). In contrast to classic Ewing sarcoma, these tumors occur preferentially in the soft tissue (90%) and in an older age group (young adults). Microscopically, CIC–DUX4–positive SRC/SCTs are associated with a higher degree of heterogeneity in nuclear shape and size compared with the consistent appearance seen with classic Ewing sarcoma. In some tumors, the neoplastic cells may be spindled. Furthermore, the CD99 immunostain is less diffuse, ranging from patchy to occasionally negative. Preliminary data regarding neoadjuvant therapy and response in metastatic disease indicate that this sarcoma subtype is less sensitive than Ewing sarcoma to standard chemotherapy agents (doxorubicin/ifosfamide or combination five-drug therapy with vincristine/doxorubicin/cyclophosphamide with ifosfamide/etoposide). However, the finding of a CIC rearrangement in nonpediatric patients with an *EWSR1*-negative SRC/SCT may support adapting the therapeutic plan according to the Ewing sarcoma family of tumors rather than following the adult-type soft tissue sarcoma guidelines.

BCOR–CCNB3–positive SRC/SCTs. A novel X-chromosomal paracentric inversion, resulting in a BCOR–CCNB3 fusion, was described recently in a subset of SRC/SCTs occurring preferentially in bone and often in young male patients. Despite remarkable clinical and pathological (some tumors may contain spindle cells) similarities with the Ewing sarcoma group, gene profiling and single-nucleotide polymorphism array analyses indicate that this group of tumors is biologically distinct from Ewing sarcoma and does not share the *EWSR1*–ETS expression signature. The latter subset may be identified by detecting CCNB3 overexpression using IHC.

Chordoma

T gene, encoding the protein brachyury, has been implicated in the pathogenesis of chordoma. Brachyury is a tissue-specific transcription factor expressed in the nucleus of notochord cells and is essential for proper notochord development and maintenance. Copy number gain of *T* gene (amplifications, polysomy, minor allelic gain) has been reported in sporadic chordomas, with similar percentages in sacrococcygeal, mobile spine, and skull base tumors.

Recently, a common genetic variant in *T* (rs2305089) was significantly associated with the risk of sporadic chordoma. The susceptibility related to *T*, however, appears to be complex, involving multiple mechanisms, including *T* duplication (essentially seen only in families), and multiple common and rare

38.2. Bone: Spine

variants. Among sporadic cases, another common variant (rs3816300) was significantly associated with risk, and the association was significantly stronger in cases with early-age onset, including cases of skull base chordoma.

Update on Molecular Aberrations in Relation to Prognosis

Ewing Sarcoma/PNET

Based on retrospective studies, the survival of patients whose tumors contain the type 1 EWSR1–FLI1 fusion appears to be better than that of patients with other EWSR1–FLI1 fusion types. However, in contrast, prospective evaluation did not confirm a prognostic benefit for type 1 EWSR1–FLI1 fusions. The EWSR1–ERG fusion is associated with clinical phenotypes indistinguishable from those of EWSR1–FLI1–positive Ewing sarcoma. Whole-genome sequencing has shown that Ewing sarcomas harboring mutations in *STAG2* and *TP53* have a poor outcome.

Risk Assessment Models

The AJCC recently established guidelines that will be used to evaluate published statistical prediction models for the purpose of granting endorsement for clinical use. Although this is a monumental step toward the goal of precision medicine, this work was published only very recently. Therefore, the existing models that have been published or may be in clinical use have not yet been evaluated for this cancer site by the Precision Medicine Core of the AJCC. In the future, the statistical prediction models for this cancer site will be evaluated, and those that meet all AJCC criteria will be endorsed.

Recommendations for Clinical Trial Stratification

The new staging strategies for appendicular skeleton, trunk, skull, and facial bones; spine; and pelvis should be incorporated in clinical trial design. Additionally, stratification based on surgical margin reporting (R0, R1, and R2) is strongly recommended. As newly modified, reporting of pathological grade should use a three-grade system.

Bibliography

1. Anderson ME. Update on Survival in Osteosarcoma. *Orthop Clin North Am*. Jan 2016;47(1):283-292.
2. Borys D, Canter RJ, Hoch B, et al. P16 expression predicts necrotic response among patients with osteosarcoma receiving neoadjuvant chemotherapy. *Human pathology*. 2012;43(11):1948-1954.
3. Carter JM, Inwards CY, Jin L, et al. Activating GNAS mutations in parosteal osteosarcoma. *The American journal of surgical pathology*. Mar 2014;38(3):402-409.
4. Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. *Cell reports*. Apr 10 2014;7(1):104-112.

38.2. Bone: Spine

5. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. *Clinical orthopaedics and related research*. Jun 2007;459:40-47.
6. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. *J Clin Oncol*. Feb 1994;12(2):423-431.
7. Duhamel LA, Ye H, Halai D, et al. Frequency of Mouse Double Minute 2 (MDM2) and Mouse Double Minute 4 (MDM4) amplification in parosteal and conventional osteosarcoma subtypes. *Histopathology*. Jan 2012;60(2):357-359.
8. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. *Clinical orthopaedics and related research*. Nov-Dec 1980;153(153):106-120.
9. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. *Journal of Clinical Oncology*. 2015;33(27):3036-3046.
10. Herrmann BG, Kispert A. The T genes in embryogenesis. *Trends in genetics : TIG*. Aug 1994;10(8):280-286.
11. Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. *J Clin Oncol*. Sep 20 2015;33(27):3029-3035.
12. Italiano A, Sung YS, Zhang L, et al. High prevalence of CIC fusion with double-homeobox (DUX4) transcription factors in EWSR1-negative undifferentiated small blue round cell sarcomas. *Genes Chromosomes Cancer*. Mar 2012;51(3):207-218.
13. Kattan MW, Hess KR, Amin MB, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. *CA: a cancer journal for clinicians*. Jan 19 2016.
14. Kelley MJ, Shi J, Ballew B, et al. Characterization of T gene sequence variants and germline duplications in familial and sporadic chordoma. *Human genetics*. Oct 2014;133(10):1289-1297.
15. Kispert A, Koschorz B, Herrmann BG. The T protein encoded by Brachyury is a tissue-specific transcription factor. *The EMBO journal*. Oct 2 1995;14(19):4763-4772.
16. Leerapun T, Hugate RR, Inwards CY, Scully SP, Sim FH. Surgical management of conventional grade I chondrosarcoma of long bones. *Clinical orthopaedics and related research*. Oct 2007;463:166-172.
17. Lin PP, Jaffe N, Herzog CE, et al. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. *Cancer*. Feb 1 2007;109(3):603-611.
18. Liu X, Kato Y, Kaneko MK, et al. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. *Cancer medicine*. 2013;2(6):803-814.
19. Ozaki T, Flege S, Liljenqvist U, et al. Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. *Cancer*. Feb 15 2002;94(4):1069-1077.
20. Peabody TD GC, Simon MA. Evaluation and staging of musculoskeletal neoplasms. *The Journal of bone and joint surgery. American volume*. 1988;80(A):1204-1218.
21. Peters TL, Kumar V, Polikepahad S, et al. BCOR-CCNB3 fusions are frequent in undifferentiated sarcomas of male children. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. Apr 2015;28(4):575-586.

38.2. Bone: Spine

22. Pillay N, Plagnol V, Tarpey PS, et al. A common single-nucleotide variant in T is strongly associated with chordoma. *Nature genetics*. 2012;44(11):1185-1187.
23. Presneau N, Shalaby A, Ye H, et al. Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. *J Pathol*. Feb 2011;223(3):327-335.
24. Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis. A review of sixty-four cases. *The Journal of bone and joint surgery. American volume*. Nov 2001;83-A(11):1630-1642.
25. Reith JD, Horodyski MB, Scarborough MT. Grade 2 chondrosarcoma: stage I or stage II tumor? *Clinical orthopaedics and related research*. Oct 2003(415):45-51.
26. Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ. Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. *The Journal of bone and joint surgery. American volume*. May 1994;76(5):649-656.
27. Saifuddin A. The accuracy of imaging in the local staging of appendicular osteosarcoma. *Skeletal radiology*. Apr 2002;31(4):191-201.
28. Salinas-Souza C, De Andrea C, Bihl M, et al. GNAS mutations are not detected in parosteal and low-grade central osteosarcomas. *Modern Pathology*. 2015;28(10):1336-1342.
29. Schoenfeld AJ, Hornicek FJ, Pedlow FX, et al. Osteosarcoma of the spine: experience in 26 patients treated at the Massachusetts General Hospital. *The spine journal : official journal of the North American Spine Society*. Aug 2010;10(8):708-714.
30. Schwab J, Gasbarrini A, Bandiera S, et al. Osteosarcoma of the mobile spine. *Spine*. Mar 15 2012;37(6):E381-386.
31. Söderstrom M, Ekfors TO, Böhling TO, Teppo LH, Vuorio EI, Aro HT. No improvement in the overall survival of 194 patients with chondrosarcoma in Finland in 1971-1990. *Acta orthopaedica*. 2003;74(3):344-350.
32. Stacy GS, Mahal RS, Peabody TD. Staging of bone tumors: a review with illustrative examples. *AJR. American journal of roentgenology*. Apr 2006;186(4):967-976.
33. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. *Cell*. Jan 7 2011;144(1):27-40.
34. Szymanska J, Mandahl N, Mertens F, Tarkkanen M, Karaharju E, Knuutila S. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: a combined cytogenetic and comparative genomic hybridization study. *Genes Chromosomes Cancer*. May 1996;16(1):31-34.
35. Tabareau-Delalande F, Collin C, Gomez-Brouchet A, et al. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. Jul 2013;26(7):911-921.
36. Talac R, Yaszemski MJ, Currier BL, et al. Relationship between surgical margins and local recurrence in sarcomas of the spine. *Clinical orthopaedics and related research*. 2002;397:127-132.
37. Tirode F, Surdez D, Ma X, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. *Cancer Discov*. Nov 2014;4(11):1342-1353.

38.2. Bone: Spine

38. Vujovic S, Henderson S, Presneau N, et al. Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. *J Pathol*. Jun 2006;209(2):157-165.
39. Wuisman P, Enneking W. Prognosis for patients who have osteosarcoma with skip metastasis. *The Journal of Bone & Joint Surgery*. 1990;72(1):60-68.
40. Yang M. Prognostic role of pathologic fracture in osteosarcoma: Evidence based on 1,677 subjects. *J Cancer Res Ther*. Apr-Jun 2015;11(2):264-267.
41. Yoshida A, Ushiku T, Motoi T, et al. MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma: correlation with a dedifferentiated subtype. *The American journal of surgical pathology*. Mar 2012;36(3):423-431.
42. Yoshida A, Ushiku T, Motoi T, et al. Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. Sep 2010;23(9):1279-1288.
43. Morrison WB, Weissman BN, Kransdorf MJ, et al. ACR Appropriateness Criteria for Primary Bone Tumors. 2013; <https://acsearch.acr.org/docs/69421/Narrative/>. Accessed January 25, 2016, 2016.